Medprin to acquire Yijie Medical outright in share-and-cash deal
Medprin Regenerative Medical Systems plans to buy 100% of Yijie Medical using shares and cash, taking the target private into its Shenzhen-listed platform and extending the use of listed paper as acquisition currency.
The context
China's medical-device sector is fragmented. Hundreds of small makers hold registrations for niche products but lack the sales force to reach hospitals nationwide. Listed companies have the distribution and the paper to buy them.
Medprin is using both. A share-and-cash structure preserves cash for operations while giving Yijie's owners a liquid stake, a combination that has become common as valuations have fallen.
The counter-argument
The bear case is dilution. Every share issued to Yijie's owners reduces the claim of existing holders on Medprin's future earnings, and without a disclosed price there is no way to judge whether the target is worth the paper.
There is also an integration risk that is specific to medtech: registrations, clinical data and hospital relationships do not transfer as cleanly as a factory. A roll-up that adds products without adding sales capacity can leave the acquirer with a larger cost base and the same revenue.
What happens next
Watch the formal agreement for the valuation and the share ratio, then the first full year of combined revenue. If Medprin's sales force can push Yijie's products through existing channels, the deal works; if revenue merely adds up, the premium is hard to justify.
From China Fund, 17 November 2026.
Original source: China Fund · 17 Nov 2026
